Search
Vaccines Treatment Options
A collection of 953 research studies where Vaccines is the interventional treatment. These studies are located in the United States . Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
145 - 156 of 953
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Human Immune Responses to Yellow Fever Vaccination
Completed
The goal of this study is to use the live attenuated Yellow Fever Vaccine as a safe and effective model for viral infection to understand human immune response to viral antigens. Study participants will receive the yellow fever vaccine and participation in the study may be as short as one month or as long as one year, depending on immune responses.
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
04/25/2025
Locations: The Hope Clinic of the Emory Vaccine Center, Decatur, Georgia
Conditions: Yellow Fever
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
Active Not Recruiting
This is a phase 1b study of P30-linked EphA2, CMV pp65, and survivin vaccination (collectively called the P30-EPS vaccine) in HLA-A\*0201 positive patients with a newly diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant glioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: The Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina
Conditions: Glioma, Malignant
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
Active Not Recruiting
This phase I trial studies the side effects and best dose of vaccine therapy when given together with sargramostim in treating patients with locally advanced or metastatic pancreatic cancer that cannot be removed by surgery. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy direc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Locally Advanced Pancreatic Adenocarcinoma
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
Completed
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: North Alabama Research Center, Athens, Alabama +320 locations
Conditions: Influenza, Human
Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations
Completed
To determine whether providing a recombinant booster COVID-19 vaccine improves sustained humoral and cell-mediated immunogenicity against SARS-CoV-2 in immunosuppressed patients with Inflammatory Bowel Disease (IBD) and/or solid organ transplant recipients. 120 participants will be enrolled and can expect to be on study for 6 months.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/18/2025
Locations: UW School of Medicine and Public Health, Madison, Wisconsin
Conditions: Immunosuppression, COVID-19
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
Recruiting
The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection.
The secondary objectives of the study are to observe short term clinical outcomes of prevalent HPV genotype-specific anogenital infections in adults living with HIV who complete the three-dose Gardasil-9 vaccine series, and to determine the protection afforded by Gardasil vaccine over time in previou... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/15/2025
Locations: University Medical Center New Orleans, New Orleans, Louisiana
Conditions: Papillomavirus Vaccines, Human Immunodeficiency Virus, Papillomavirus Infection, Serology, Cervical Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Oral Cavity Infection
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
Active Not Recruiting
We are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.
Gender:
ALL
Ages:
Between 15 years and 26 years
Trial Updated:
04/09/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Immunization, Efficacy, Human Papilloma Virus
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
Recruiting
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in use, 20vPnC (Prevnar 20®) or another licensed pneumococcal vaccine.
To ensure that the new vaccine (PG4) stays stable, it is placed in a liquid mixture of sterile water and other substances (a solution). This study will also test if there is a difference in the safety and... Read More
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
03/28/2025
Locations: Northwest Arkansas Pediatric Clinic, Fayetteville, Arkansas +56 locations
Conditions: Pneumococcal Disease
A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults
Completed
To assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with HZ/su vaccine and its safety in older adults, aged \>=50 years of age.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/28/2025
Locations: GSK Investigational Site, Daphne, Alabama +26 locations
Conditions: Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
Active Not Recruiting
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from retu... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/27/2025
Locations: University of South Alabama Mitchell Cancer Institute, Mobile, Alabama +173 locations
Conditions: Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
Active Not Recruiting
This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Smoldering Plasma Cell Myeloma
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Recruiting
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
Gender:
FEMALE
Ages:
Between 27 years and 45 years
Trial Updated:
03/25/2025
Locations: University of Texas Medical Branch, Galveston, Texas
Conditions: Immunization, HPV Infection, Human Papillomavirus
145 - 156 of 953